hVIVO (AIM:HVO) has signed a Clinical Trial Agreement to deliver a Phase 2a human challenge trial for Traws Pharma (NASDAQ: TRAW), a clinical‑stage biopharma developing therapies for respiratory viral diseases. The study will use hVIVO’s Influenza Human Challenge Study Model to test tivoxavir marboxil (TXM), a prophylactic, oral CAP‑dependent endonuclease inhibitor aimed at seasonal and avian influenza.
The trial is randomised, double‑blinded and placebo‑controlled and will recruit approximately 150 healthy adults at hVIVO’s Canary Wharf quarantine site. hVIVO’s FluCamp arm will handle participant recruitment and its on‑site virology laboratory will perform all lab work. The company expects the study to commence in H1 2026, with the majority of revenue recognised in 2026.
"Through our Influenza Human Challenge Trial Model, we will be able to deliver fast, controlled, high‑quality efficacy data for Traws Pharma that would not be achievable in traditional field studies, reducing development risk for TXM and improving capital efficiency. By leveraging key synergies across our integrated clinical development services and conducting participant recruitment all under one roof, this trial illustrates our unique value proposition as a true full‑service clinical development partner," Yamin 'Mo' Khan, Chief Executive Officer of hVIVO, said.
hVIVO notes it has inoculated more than 5,000 participants across 2,477 influenza, RSV and other viral HCTs and cites prior client work that supported deals such as the acquisition of Cidara Therapeutics by Merck.
